Jobevne / Abevmy / Krabeva
Bevacizumab biosimilar developed by Biocon Biologics, development code Bmab-100. Reference product Avastin.
Brands by market: Jobevne (USA); Abevmy (EU, UAE); Krabeva (India) · Commercial partner or holder: Biocon Biologics · Company profile
FDAApr 2025approved
EMAApr 2021authorised
MHRALicenseddate not shown
PMDANot listed
HCNov 2021approved
CDSCOMay 2017permitted
EDEFeb 2022registered
Approved or registered in 6 of 7 markets
Connections
About Jobevne / Abevmy / Krabeva
Biocon's bevacizumab was first permitted in India in 2017, sold there as Krabeva. It reached Europe in 2021 as Abevmy, Canada the same year, the UAE in 2022, and the United States in April 2025 as Jobevne. It is the only bevacizumab biosimilar with approvals in six of the seven markets covered here.
Status by market
FDA
United States · Jobevne
US Food and Drug AdministrationApprovedBrand
Jobevne
Holder or applicant
Biocon Biologics Inc.
Pathway
351(k)
Approved
Apr 2025
Application or permission
761175
Licence type
351(k) biosimilar, not interchangeable
Reference product in the Purple Book
Avastin
Marketing status (Purple Book)
Prescription, marketed
Presentations
100 mg/4 mL, 400 mg/16 mL
Source
S001 (FDA); S016 (FDA Purple Book) · checked Sep 2026
EMA
European Union · Abevmy
European Medicines Agency and European CommissionApprovedBrand
Abevmy
Holder or applicant
Biosimilar Collaborations Ireland Limited
Pathway
Centralised (Article 10(4))
Approved
Apr 2021
Application or permission
EMEA/H/C/005327
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom · Abevmy
Medicines and Healthcare products Regulatory AgencyApprovedBrand
Abevmy
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
25 mg/mL vials
Source
S023 (MHRA Products) · checked Sep 2026
PMDA
Japan
Not listed by PMDA.
HC
Canada · Abevmy
Health CanadaApprovedBrand
Abevmy
Holder or applicant
Biocon Biologics Canada INC
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Nov 2021
Application or permission
DIN 02522160, 02522179
Presentations
100, 400 mg
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India · Krabeva
Central Drugs Standard Control OrganisationApprovedBrand
Krabeva
Holder or applicant
Biocon Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2017
Application or permission
MF-90/2017; BULK-91/2017
Indications as licensed
Colorectal, NSCLC, renal, ovarian, cervical cancer, glioblastoma
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S014 (CDSCO) · checked Sep 2026
EDE
United Arab Emirates · Abevmy
Emirates Drug EstablishmentRegisteredBrand
Abevmy
Holder or applicant
Biocon Biologics Limited, India · UAE supplier Lunatus Drug Store LLC
Pathway
Registered medical product
Registered
Feb 2022
Presentations
400 mg vial (Feb 2022); 100 mg vial (Jun 2022)
Source
S018 (UAE Emirates Drug Establishment) · checked Sep 2026
Other developers in the same markets
Where Jobevne / Abevmy / Krabeva holds an approval, these are the other bevacizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| FDA | 5 | Amgen (Mvasi), Bio-Thera Solutions (Avzivi), Celltrion (Vegzelma), Pfizer (Zirabev), mAbxience (Alymsys / Oyavas) |
| EMA | 6 | Amgen (Mvasi), Bio-Thera Solutions (Avzivi), Celltrion (Vegzelma), Pfizer (Zirabev), Samsung Bioepis (Aybintio), mAbxience (Alymsys / Oyavas) |
| MHRA | 5 | Celltrion (Vegzelma), Not stated in the MHRA list (Versavo), Pfizer (Zirabev), Samsung Bioepis (Aybintio), mAbxience (Alymsys / Oyavas) |
| HC | 5 | Amgen (Mvasi), Apotex (Bambevi), Celltrion (Vegzelma), Pfizer (Zirabev), Samsung Bioepis (Aybintio) |
| CDSCO | 7 | CuraTeQ Biologics (CuraTeQ bevacizumab), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab), Zydus Lifesciences (Zydus bevacizumab) |
| EDE | 2 | Amgen (Mvasi), Pfizer (Zirabev) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Biocon Biologics: Biocon human insulin, Bosaya / Aukelso / Vevzuo / Evfraxy, Fulphila / Vivlipeg / Biopegfil, Kirsty, Ogivri / CANMAb, Semglee, Yesafili, Yesintek / Usrenty.
Chronology
- CDSCOMay 2017CDSCO permission granted as Krabeva
- EMAApr 2021Authorised by the European Commission as Abevmy
- HCNov 2021Notice of Compliance, Health Canada as Abevmy
- EDEFeb 2022Registered in the UAE as Abevmy
- FDAApr 2025Approved by FDA as Jobevne
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)S018UAE Emirates Drug Establishment, registered medical product directory Primary (regulator)S022Health Canada, Drug Product Database data extract (active and inactive product files, biosimilar table) Primary (regulator)S023MHRA Products, substance lists of licensed medicines (products.mhra.gov.uk) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.